China Resources Pharmaceuticals: intends to sell a 5.88% stake in Tianmai Biologics for 510 million yuan

LightningPacketLoss · 2026-03-17T09:33:14+00:00

China Resources Pharmaceuticals' wholly-owned subsidiary has initiated the sale of approximately 5.88% equity stake in Hefei Tianmai Biotechnology, with an initial listing reserve price of 510 million yuan. This equity sale is independent of the previous equity sale matters announced.

LightningPacketLoss

2026-03-17 09:33:14

Abstract generation in progress

Recently, China Resources Pharmaceutical announced that its wholly owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., has initiated a potential sale of approximately 5.88% of its equity stake in Hefei Tianmai Biotechnology Development Co., Ltd., with an initial listing price of about 510 million yuan. This potential sale is independent of and unrelated to the sale of certain equity interests in Tianmai Biotechnology previously announced by the company.

(China Resources Pharmaceutical Announcement)

(Editor: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.